Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study

Jacqueline F. Wang, Jihao Zhou, Reema K. Tawfiq, Han W. Tun, Javier L. Munoz, Jonas Paludo, Muhamad Alhaj Moustafa, Steven R. Hwang, Izel Okcu, Catherine S. Diefenbach, Jia Ruan, Peter Martin, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang

Blood (2024) 144 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2024-204268

Published: 2024

Journal Articles

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Christopher J. Forlenza, Opeyemi Jegede, Stephen M. Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E. Amengual, Peter D. Cole, Brad S. Kahl, Catherine S. Diefenbach

Blood (2024) 144 (Supplement 1): 4427.

https://doi.org/10.1182/blood-2024-201624

Published: 2024

Journal Articles

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Sairah Ahmed, John F. DiPersio, James H Essell, Catherine S. Diefenbach, Miguel Angel Perales, Cristina Castilla-Llorente, Saurabh Dahiya, Sohail Chaudhry, Heng Xu, Yi Liu, Christie Fanton, Zachary Lee, Mario Q. Marcondes, Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk

Blood (2024) 144 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2024-203576

Published: 2024

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 570.

https://doi.org/10.1182/blood-2024-199845

Published: 2024

Journal Articles

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Blood (2024) 144 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2024-200719

Published: 2024

Journal Articles

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Catherine S. Diefenbach, Andrew D. Zelenetz, Charles Herbaux, Monica Tani, Roch Houot, Mariana Bastos-Oreiro, Hervé Tilly, Thomas Gastinne, Catherine Thieblemont, Wilfred Leung, Katerina Hatzi, Murali Kesavan, Simona Barlera, Michelle Boyer, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 577.

https://doi.org/10.1182/blood-2024-198624

Published: 2024

Journal Articles

Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study

Catherine S. Diefenbach, Paolo F. Caimi, Nakhle S Saba, Fernando Vargas Madueno, Mehdi Hamadani, Luis E. Fayad, Peter A. Riedell, Andrew Gillis-Smith, Stephen Simko, Victor Orellana-Noia, Maria Filippou-Frye, Amy V. Kapp, James Relf, Linda Lundberg, Lauren C. Pinter-Brown

Blood (2024) 144 (Supplement 1): 987.

https://doi.org/10.1182/blood-2024-198452

Published: 2024

Journal Articles

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Blood (2024) 144 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2024-197923

Published: 2024

Journal Articles

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood (2024) 144 (Supplement 1): 4501.

https://doi.org/10.1182/blood-2024-199281

Published: 2024

Journal Articles

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Bruce D. Cheson, Nancy L. Bartlett, Betsy R. LaPlant, Hun Ju Lee, Ranjana H. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana Feldman, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2024-207424

Published: 2024

Journal Articles

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Catherine S Diefenbach, Opeyemi Jegede, Stephen M Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E Amengual, Christopher J. Forlenza, Peter D. Cole, Nancy L. Bartlett, Kevin A. David, Ranjana H. Advani, Richard F. Ambinder, Sachdev Thomas, Sami Ibrahimi, Brad S. Kahl

Blood (2023) 142 (Supplement 1): 607.

https://doi.org/10.1182/blood-2023-184531

Published: 2023

Journal Articles

Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Andrew D. Zelenetz, Catherine S. Diefenbach, Charles Herbaux, Monica Tani, Roch Houot, Mariana Bastos-Oreiro, Herve Tilly, Thomas Gastinne, Catherine Thieblemont, Ethan Troy-Barnes, Stefano Olivieri, Murali Kesavan, Manisha Kanwar, Simona Barlera, Katerina Hatzi, Yanwen Jiang, Michelle Boyer, Franck Morschhauser

Blood (2023) 142 (Supplement 1): 439.

https://doi.org/10.1182/blood-2023-174855

Published: 2023

Journal Articles

Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)

Blood (2023) 142 (Supplement 1): 4382.

https://doi.org/10.1182/blood-2023-174903

Published: 2023

Journal Articles

A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group

Jacqueline F. Wang, Jihao Zhou, Steven R Hwang, Catherine S Diefenbach, Jia Ruan, Peter Martin, Jonas Paludo, Javier L. Munoz, Stephen M Ansell, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan, Grzegorz S. Nowakowski, Yucai Wang

Blood (2023) 142 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2023-179611

Published: 2023

Journal Articles

Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404

Jonathon B. Cohen, Opeyemi Jegede, Craig A. Portell, Mehdi Hamadani, Catherine S. Diefenbach, Kevin A. David, Christopher D. Fletcher, Daniel J. Landsburg, Suparna Mantha, Brad S. Kahl

Blood (2022) 140 (Supplement 1): 6487–6488.

https://doi.org/10.1182/blood-2022-164710

Published: 2022

Journal Articles

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Catherine S. Diefenbach, Brad S. Kahl, Lalita Banerjee, Andrew K. McMillan, Fiona Miall, Javier Briones, Raul Cordoba, John M. Burke, Jamie Hirata, Sunil Sharma, Lisa Musick, Pau Abrisqueta Costa

Blood (2022) 140 (Supplement 1): 2286–2288.

https://doi.org/10.1182/blood-2022-157720

Published: 2022

Journal Articles

Preclinical Development of Lymphotoxin Beta Receptor-Overexpressing CAR T Cells Demonstrates Potentiation of CAR T Cell Antitumor Activity

Mateusz Legut, Maria Guarino, Xinhe Xue, Congyi Lu, Radha Vyas, Catherine S. Diefenbach, Neville Sanjana

Blood (2022) 140 (Supplement 1): 10235–10236.

https://doi.org/10.1182/blood-2022-163230

Published: 2022

Journal Articles

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Blood (2022) 140 (Supplement 1): 6436–6438.

https://doi.org/10.1182/blood-2022-163235

Published: 2022

Journal Articles

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Jacob D. Soumerai, Catherine S. Diefenbach, Felipe Samaniego, Abhijeet Kumar, Michaela L. Tsai, Adam S. Asch, Deepa Jagadeesh, Vaishalee P. Kenkre, Izidore S. Lossos, Huda Salman, Farrukh T. Awan, Lu Miao, Richard G. Ghalie, Andrew D. Zelenetz

Blood (2022) 140 (Supplement 1): 189–191.

https://doi.org/10.1182/blood-2022-157563

Published: 2022

Journal Articles

Follicular Lymphoma Transcriptional Signatures Identify Heterogenous Biological Subtypes with Distinct Clinical Outcomes

Matthew M Klairmont, Catherine S. Diefenbach, Christopher Y. Park

Blood (2022) 140 (Supplement 1): 3504–3505.

https://doi.org/10.1182/blood-2022-170523

Published: 2022

NARROW

Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)

A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group

Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Preclinical Development of Lymphotoxin Beta Receptor-Overexpressing CAR T Cells Demonstrates Potentiation of CAR T Cell Antitumor Activity

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Follicular Lymphoma Transcriptional Signatures Identify Heterogenous Biological Subtypes with Distinct Clinical Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only